Literature DB >> 1535302

Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers.

C A Naranjo1, C X Poulos, K E Bremner, K L Lanctôt.   

Abstract

In previous studies serotonin uptake inhibitors such as citalopram decreased alcohol consumption in alcoholics. The mechanism of the effect is not fully understood. This study tested the hypothesis that it is mediated by changes in desire to drink and alcohol effects. After a 1-week baseline period, subjects (13 men and three women; aged 26 to 69 years; healthy, nondepressed, alcohol-dependent drinkers [mean, 6.6 drinks per day]) were randomized in a double-blind fashion to receive 40 mg/day citalopram and placebo for 1 week each, separated by a 1-week washout period. Daily standard alcoholic drinks (13.6 gm ethanol), nonalcoholic drinks, and tobacco use were recorded; evening urine samples were taken; and interest, desire, craving, and liking for alcohol were rated. Medical status, depression, and anxiety were assessed weekly, but no other treatment or advice was given. Daily alcoholic drinks significantly decreased during citalopram treatment (mean +/- SEM = 4.6 +/- 0.6) compared with placebo (5.7 +/- 0.8; p = 0.01), and the average decrease was 17.5%. Percentage of days abstinent increased during citalopram administration (27.7% +/- 5.7%) compared with placebo (15.5% +/- 3.7%; p less than 0.01). Citalopram decreased interest, desire, craving, and liking for alcohol (all p less than 0.05). There was clear internal validation of these measures in that variations in each correlated with alcohol consumption (all r greater than 0.5, p less than 0.05). Nonalcoholic drinks, self-reports of cigarettes smoked (daily smokers), and body weight did not change significantly. In experimental bar sessions, after the citalopram and placebo periods, subjects were required to consume as many of 18 minidrinks as possible (equivalent to six standard drinks) at 5-minute intervals. Subjects rated their desire for alcohol, intoxication, and mood. Citalopram had no significant effects on the desirability of alcohol or subjective feelings of intoxication. The findings indicate that serotonin uptake inhibitors may act by decreasing the urge to drink and the reinforcing effects of alcohol. Also, a naturalistic outpatient trial is a sensitive, simple, and economic procedure for detecting these drug effects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1535302     DOI: 10.1038/clpt.1992.85

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

Review 1.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 2.  Pharmacotherapy of alcohol use disorders: seventy-five years of progress.

Authors:  Leah R Zindel; Henry R Kranzler
Journal:  J Stud Alcohol Drugs Suppl       Date:  2014

Review 3.  Clinical issues related to the costs of alcoholism.

Authors:  M O Howard; R W McGuffin; A J Saxon; K L Sloan; R D Walker
Journal:  Pharmacoeconomics       Date:  1996-02       Impact factor: 4.981

Review 4.  Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 5.  Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities.

Authors:  M Soyka
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 6.  Recommended drug treatment strategies for the alcoholic patient.

Authors:  A Schaffer; C A Naranjo
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

7.  Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes.

Authors:  Karin Herrlin; Norio Yasui-Furukori; Gunnel Tybring; Jolanta Widén; Lars L Gustafsson; Leif Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 8.  Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.

Authors:  Bankole A Johnson
Journal:  Biochem Pharmacol       Date:  2007-08-09       Impact factor: 5.858

9.  Effects of rapid tryptophan depletion on mood and urge to drink in patients with co-morbid major depression and alcohol dependence.

Authors:  Amira Pierucci-Lagha; Richard Feinn; Vania Modesto-Lowe; Robert Swift; Maggie Nellissery; Jonathan Covault; Henry R Kranzler
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

10.  Neurodevelopmental liabilities in alcohol dependence: central serotonin and dopamine dysfunction.

Authors:  Claudio A Naranjo; Alan Y Chu; Lescia K Tremblay
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.